Severine Tabone-Eglinger
Overview
Explore the profile of Severine Tabone-Eglinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
189
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherradi S, Roux S, Dupuy M, Tabone-Eglinger S, Tuaillon E, Ziol M, et al.
Sci Rep
. 2025 Jan;
15(1):1179.
PMID: 39774014
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Treating HCC is challenging because of the poor drug effectiveness and the lack of tools to predict...
2.
Collet L, Telouk P, Albarede F, Girodet M, Maqua C, Rogasik M, et al.
Metabolomics
. 2024 Nov;
20(6):129.
PMID: 39520592
Objectives: While some metals have been reported as carcinogens or potential carcinogens, only few modern-standard datasets including a large number of elements are available. The present analysis established a first...
3.
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, et al.
Nat Commun
. 2024 Jul;
15(1):5932.
PMID: 39013886
PD-1/PD-L1 blockade has so far shown limited survival benefit for high-grade ovarian carcinomas. By using paired samples from the NeoPembrOv randomized phase II trial (NCT03275506), for which primary outcomes are...
4.
Dufresne A, Attignon V, Ferrari A, Tonon L, Boyault S, Tabone-Eglinger S, et al.
Cancer Med
. 2024 Mar;
13(7):e7115.
PMID: 38553950
Introduction: The objective was to determine the added value of comprehensive molecular profile by whole-exome and RNA sequencing (WES/RNA-Seq) in advanced and refractory cancer patients who had no molecular-based treatment...
5.
Marques Da Costa M, Zaidi S, Scoazec J, Droit R, Lim W, Marchais A, et al.
Commun Biol
. 2023 Sep;
6(1):949.
PMID: 37723198
Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To...
6.
Vogrig A, Pegat A, Villagran-Garcia M, Wucher V, Attignon V, Sohier E, et al.
Ann Neurol
. 2023 Aug;
94(6):1102-1115.
PMID: 37638563
Objective: Small-cell lung cancer (SCLC) is the malignancy most frequently associated with paraneoplastic neurological syndromes (PNS) and can trigger different antibody responses against intracellular (Hu) or neuronal surface (GABA R)...
7.
Ducarouge B, Redavid A, Victoor C, Chira R, Fonseca A, Hervieu M, et al.
Cell Death Differ
. 2023 Aug;
30(10):2201-2212.
PMID: 37633969
Drug resistance and cancer relapse represent significant therapeutic challenges after chemotherapy or immunotherapy, and a major limiting factor for long-term cancer survival. Netrin-1 was initially identified as a neuronal navigation...
8.
Tredan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444551
Background: MOST-plus is a multicenter, randomized, open-label, adaptive Phase II trial evaluating the clinical benefit of targeted treatments matched to molecular alteration in advanced/metastatic solid tumors. Sorafenib was tested on...
9.
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, et al.
Nat Genet
. 2023 Mar;
55(4):607-618.
PMID: 36928603
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using...
10.
Paternot S, Raspe E, Meiller C, Tarabichi M, Assie J, Libert F, et al.
Mol Oncol
. 2022 Dec;
18(4):866-894.
PMID: 36453028
Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited therapeutic options. We evaluated the impact of CDK4/6 inhibition by palbociclib in 28 MPM cell lines including 19 patient-derived ones,...